Kyowa Kirin Presents Data at EORTC-Cutaneous Lymphoma Task Force Meeting Showing Significantly Improved Quality of Life for Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS) on Mogamulizumab

Tokyo (ots/PRNewswire) -

First oral presentation of Quality of Life data from the phase
III trial (MAVORIC), the largest randomised trial in MF and SS -
the two most common types of Cutaneous T Cell Lymphoma[1]

Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces that Quality
of Life (QoL) data from the pivotal MAVORIC trial will be the subject
of an oral presentation,[2] at the European Organization for Research
and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF)
meeting, September 27-29, St. Gallen, Switzerland. A case report of a
long-term responder in the MAVORIC[3] trial will also be reported as
a poster.[4]

Presentation titles at the 2018 EORTC CLTF Mtg:

- Quality of Life in Cutaneous T Cell Lymphoma Patients Treated with
the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat:
Results from MAVORIC
[Abstract 105; Fri 28th Sept, 11am-12.30pm]
- Long-term complete remission induced by mogamulizumab in a severe
Sezary patient, together with five different possible autoimmune
manifestations [Abstract
#059; Case study poster (external)]

QoL was a secondary end-point of the phase 3 MAVORIC
(mogamulizumab versus vorinostat in previously treated cutaneous
T-cell lymphoma) trial and significant improvements were seen with
mogamulizumab versus vorinostat as early as cycle three and continued
throughout. Using QoL measurements including Skindex-29, Functional
Assessment of Cancer Therapy-General (FACT-G) and EuroQol-5D-3L
(EQ-5D-3L), clinically meaningful improvements in patient-reported
skin-related symptoms and preservation of physical well-being were
observed. >= 61% of mogamulizumab patients reported
clinically-meaningful improvements in skin-related symptoms from
Cycles 3 through to 11 and significantly more vorinostat patients
reported clinically-meaningful declines in physical well-being in
Cycles 1 through to 11. There was also delay in patient reported
deterioration in the Skindex-29 Summary and Emotions subscores in
patients given mogamulizumab.

Dr Pierluigi Porcu, Sidney Kimmel Cancer Center at Jefferson
Health, Thomas Jefferson University, USA elaborates further on the
data: "Cutaneous T cell lymphomas are highly visible cancers, that
can significantly impact patients' QoL. The effects of the disease
can be extremely debilitating, which in turn can affect the patient
both mentally and emotionally. We are extremely excited about these
findings as it demonstrates the potential benefits of mogamulizumab
beyond efficacy and, in particular, for outcomes that are especially
important to people affected by CTCL. It is reassuring to see quick